Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth has received approval from the FDA for Xyntha for patients with hemophilia A.
Subscribe to our email newsletter
Xyntha is a recombinant antihemophilic factor used for both the control and prevention of bleeding episodes and surgical prophylaxis. Xyntha is considered as the only recombinant factor VIII product to utilize an entirely synthetic (non- human and non-animal based) purification process in its manufacture.
Robert Ruffolo, Jr. president, Wyeth research, and senior vice president of Wyeth, said: “Xyntha is important for hemophilia A patients because it establishes a new standard in recombinant factor VIII product purification technology.”